James Rph - UroGen Pharma Executive Quality
| URGN Stock | USD 20.10 0.11 0.54% |
Executive
James Rph is Executive Quality of UroGen Pharma
| Address | 400 Alexander Park Drive, Princeton, NJ, United States, 08540 |
| Phone | 646 768 9780 |
| Web | https://www.urogen.com |
UroGen Pharma Management Efficiency
The company has return on total asset (ROA) of (0.3396) % which means that it has lost $0.3396 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2026, Return On Equity is likely to grow to 13.62, while Return On Tangible Assets are likely to drop (0.42). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 17th of February 2026, Other Current Assets is likely to grow to about 12 M, though Net Tangible Assets are likely to grow to (97.6 M).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Martin Gilligan | Phathom Pharmaceuticals | N/A | |
| Kenneth MD | Xencor Inc | N/A | |
| Isabelle PharmD | Oculis Holding AG | N/A | |
| Nancy Phelan | Phathom Pharmaceuticals | 57 | |
| Mr MD | BridgeBio Oncology Therapeutics | N/A | |
| James MD | AnaptysBio | 62 | |
| JD Esq | Phathom Pharmaceuticals | 64 | |
| Paul Cocja | Phathom Pharmaceuticals | N/A | |
| Bill JD | Phathom Pharmaceuticals | N/A | |
| Emily Butler | ProKidney Corp | N/A | |
| Anu Biswas | ProKidney Corp | N/A | |
| Bastian Dehmel | Oculis Holding AG | 53 | |
| Sylvia Cheung | Oculis Holding AG | 51 | |
| Nancy MD | Xencor Inc | 66 | |
| Martin Dahl | AnaptysBio | N/A | |
| Mark Devlin | Phathom Pharmaceuticals | N/A | |
| Joanne MD | Oculis Holding AG | 63 | |
| Christopher Phelps | Nurix Therapeutics | N/A | |
| Barbara MD | Tango Therapeutics | 68 | |
| Jason Kantor | Nurix Therapeutics | N/A | |
| Pll Jhannesson | Oculis Holding AG | 44 | |
Management Performance
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.34 |
UroGen Pharma Leadership Team
Elected by the shareholders, the UroGen Pharma's board of directors comprises two types of representatives: UroGen Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of UroGen. The board's role is to monitor UroGen Pharma's management team and ensure that shareholders' interests are well served. UroGen Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, UroGen Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dong Kim, Chief Officer | ||
| Jason JD, Chief Counsel | ||
| Sari PrutchiSagiv, Marketing Director | ||
| Jason Smith, Chief Counsel | ||
| Bryon Wornson, Advocacy Talent | ||
| Eric Zanten, Director Communications | ||
| Christopher CPA, Chief Officer | ||
| MD MPH, Senior Development | ||
| James Rph, Executive Quality | ||
| Vincent Perrone, Director Relations | ||
| DVM MBA, Chief Officer | ||
| Marina Konorty, Executive Operations | ||
| Gil Hakim, Consultant | ||
| Mark MD, Chief Officer | ||
| David Lin, Chief Officer | ||
| Christopher Degnan, Chief Officer | ||
| Ron MBA, Advisor | ||
| Timothy Simon, Senior Strategy | ||
| Elizabeth Barrett, President CEO, Director | ||
| Jeffrey MBA, Chief Officer |
UroGen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is UroGen Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -14.81 | ||||
| Return On Asset | -0.34 | ||||
| Profit Margin | (1.71) % | ||||
| Operating Margin | (1.00) % | ||||
| Current Valuation | 942.18 M | ||||
| Shares Outstanding | 46.81 M | ||||
| Shares Owned By Insiders | 3.80 % | ||||
| Shares Owned By Institutions | 96.20 % | ||||
| Number Of Shares Shorted | 10.3 M | ||||
| Price To Earning | 239.57 X |
Pair Trading with UroGen Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.Moving together with UroGen Stock
Moving against UroGen Stock
| 0.8 | DRTS | Alpha Tau Medical | PairCorr |
| 0.71 | 8VP1 | AVRICORE HEALTH INC | PairCorr |
| 0.68 | GXEA | Galapagos NV Earnings Call This Week | PairCorr |
| 0.62 | 6C1 | CytomX Therapeutics | PairCorr |
| 0.56 | DRUG | Bright Minds Biosciences | PairCorr |
The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.
The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Will Biotechnology sector continue expanding? Could UroGen diversify its offerings? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every UroGen Pharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (3.47) | Revenue Per Share | Quarterly Revenue Growth 0.09 | Return On Assets | Return On Equity |
Investors evaluate UroGen Pharma using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating UroGen Pharma's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause UroGen Pharma's market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, UroGen Pharma's market price signifies the transaction level at which participants voluntarily complete trades.